Ascendiant Capital Markets Issues Positive Forecast for RenovoRx (NASDAQ:RNXT) Stock Price

Posted by ABMN Staff on Dec 11th, 2024

RenovoRx (NASDAQ:RNXT – Free Report) had its price target hoisted by Ascendiant Capital Markets from $8.25 to $9.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

RenovoRx Stock Down 4.2 %

Shares of RenovoRx stock opened at $1.37 on Tuesday. The firm has a market cap of $32.88 million, a PE ratio of -2.40 and a beta of 1.10. The company’s fifty day simple moving average is $1.10 and its two-hundred day simple moving average is $1.12. RenovoRx has a 12-month low of $0.61 and a 12-month high of $2.35.

Institutional Inflows and Outflows

An institutional investor recently raised its position in RenovoRx stock. Geode Capital Management LLC grew its holdings in shares of RenovoRx, Inc. (NASDAQ:RNXT – Free Report) by 61.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 232,937 shares of the company’s stock after buying an additional 89,018 shares during the period. Geode Capital Management LLC owned 0.97% of RenovoRx worth $247,000 as of its most recent SEC filing. 3.10% of the stock is owned by hedge funds and other institutional investors.

About RenovoRx

(Get Free Report)

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.